---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-050317"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:44:35.971554+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CareDx acquires Naveris for $160M; Q1 revenue $118M (+39% YoY), raises 2026 guidance

## Summary
- Upfront cash $160M for Naveris, plus up to $100M in revenue milestones; expands into viral-mediated cancer MRD surveillance.
- Q1 revenue $118M (+39% YoY); Testing Services revenue $91M (+48% YoY); GAAP net income $3M vs loss $10M prior year.
- FY2026 revenue guidance raised to $447M-$465M from $420M-$444M; AEBITDA guidance raised to $43M-$57M.
- Board authorized up to $100M stock repurchase program over 24 months.
- Deal expected to close Q3 2026; neutral to FY2026 AEBITDA; Naveris $34M revenue in 2025 with 65% gross margins.

## SEC filing metadata
- accession: 0001104659-26-050317
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 9.01, 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/0001104659-26-050317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/tm2611749d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-050317
- JSON: https://secwatch.observer/filing/0001104659-26-050317.json
- Plain text: https://secwatch.observer/filing/0001104659-26-050317.txt

## Source-grounded claims
- claim_id: 139d0161c56e48662e44738d7ff5eefb77bfceb2
  claim: CareDx, Inc. reported the first quarter ended March 31, 2026 results: revenue $118 million, net income $3 million, EPS $0.05. Guidance raised.
  evidence_excerpt: for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights · Revenue of $118 million, an increase of 39% year-over-year · Testing services revenue of $91 million, an increase of 48% year-over-year, and testing services volume of approximately 54,900, an increase
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/0001104659-26-050317-index.htm
- claim_id: ff2b3808fd3c09bac141d22d9340b0e084cbee96
  claim: CareDx, Inc. entered into Merger Agreement with Naveris, Inc., Nautilus Merger Sub, Inc., and Shareholder Representative Services LLC valued at $160.0 million in cash, subject to certain customary adjustments, and up to $100.0 million in additi (effective 2026-04-28).
  evidence_excerpt: On April 28, 2026, CareDx, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Naveris, Inc., a Delaware corporation (“Naveris”), Nautilus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Shareholder Representative Services LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000110465926050317/0001104659-26-050317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.